Log In | Register
A new clinical trial for an AIDS vaccine will take place in Africa and the United States. The program, announced this week, is a collaboration between the International AIDS Vaccine Initiative (IAVI), which will lead the trial, biopharmaceutical company Crucell (Leiden, Netherlands), Harvard Medical School's Beth Israel Deaconess Medical Center, and the Ragon Institute, an organization dedicated to HIV/AIDS research.
AIDS Vaccine Trial Planned by IAVI, Crucell, Harvard, Ragon Institute
Seeded on Fri Aug 13, 2010 5:07 PM EDT
Article Source: PHARMTECH TALK- Enjoy this article? Help vote it up the 'Vine.
- Public Discussion (1)
In related news, scientists at the National Institutes of Health (NIH) announced the discovery of two human antibodies that can stop more than 90% of HIV strains from infecting human cells in the laboratory. The team, part of the Vaccine Research Center, a division of the National Institute of Allergy and Infectious Diseases at NIH, also demonstrated how one of the antibodies does this. The scientists said the antibodies could be used to design improved HIV vaccines, or could be further developed to prevent or treat HIV infection, according to the group’s press release. The work was published in Science in two articles, found here and here.
#1 - Fri Aug 13, 2010 5:11 PM EDTYou're in Easy Mode. If you prefer, you can use XHTML Mode instead. |
As a new user, you may notice a few temporary content restrictions. Click here for more info.
